Media coverage
1
Media coverage
Title Peter MacCallum Cancer Centre Researchers Detail Research in Salivary Gland Cancer (Inhibition of anti-tumour reactivity of immune cells in the salivary gland cancer: A proteomic approach). Degree of recognition International Media name/outlet NewsRX LLC Media type Web Country/Territory United States Date 14/12/24 Description Investigators discuss new findings in salivary gland cancer. According to news originating from the Peter MacCallum Cancer Centre by NewsRx editors, the research stated, "Adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), and oral squamous cell carcinoma (OSCC) respond differently to immunotherapy. Pembrolizumab, an immune checkpoint inhibitor, has been approved by the Food and Drug Administration for the treatment of squamous cell carcinomas of the head and neck region. Producer/Author NewsRX URL https://go.gale.com/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&retrievalId=0a7a8757-e8a0-477d-8d9e-7cfbcca5718c&hitCount=5501&searchType=BasicSearchForm¤tPosition=4&docId=GALE%7CA819263303&docType=Article&sort=Relevance&contentSegment=ZONE-Exclude-FT&prodId=AONE&pageNum=1&contentSet=GALE%7CA819263303&searchId=R2&userGroupName=anon%7Ed1ec168e&inPS=true Persons Rajdeep Chakraborty